Skip over main navigation
  • Log in
  • Basket: (0 items)
  • Perth Blood Institute
  • Thrombosis Australia
  • Thrombosis Australia Professionals
The Perth Blood Institute Limited
  • Search
  • Facebook
  • Linkedin
  • Email
  • Search
  • Facebook
  • Linkedin
  • Email
Login Register Subscribe Donate
Menu
  • Who we are
    • Vision, mission and values
    • What we do
    • Our facilities
    • Our team
      • Board
      • Investigators
      • Thrombosis Australia Advisory Panel
    • Work with us
  • Our clinical trials
    • Clinical trials
    • Collaborations
    • Participate in a clinical trial
    • Useful links
  • Our research
    • Current research projects
    • Research highlights
    • Research collaborations
      • PBI
      • APTIN
    • Participate in a research project
    • Published research
  • About blood disorders
    • Overview
    • Information on blood disorders
      • Haemophilia
      • Myelofibrosis (MF)
      • TTP
      • Thrombophilia
      • von Willebrand Disease
    • For patients and families
  • Personal stories
    • Living with a blood disorder
  • Get involved
    • Donate
    • Fundraise
    • Partner with us
    • Leave a gift in your will
    • Other ways to help
  • News and events
    • Latest news & info
    • Previous news
    • Significant days
    • Media
    • Upcoming events
    • Publications
  • Admin
    • Log in
    • Perth Blood Institute
    • Thrombosis Australia
    • Thrombosis Australia Professionals
  • Basket: (0 items)
  • research-highlights
  1. Our research
  2. Research highlights

Research highlights

Publications in leading medical journals

PBI’s active clinical research focuses on deep vein thrombosis, stroke, thrombophilia, thrombocytopenia, haemophilia A, recurrent miscarriage, Von Willebrand disease, leukaemia, lymphoma, myeloma, anaemia and iron overload. PBI’s research division, together with PBI’s clinical trials division, conducted early- and late-phase international clinical trials with new therapeutics developed through PBI’s clinical research.

The trials produced research publications in leading medical journals, including the Journal of Thrombosis and Haemostasis and the New England Journal of Medicine; and provided the basis for early access to new-targeted drugs for Australian patients.


Complex microRNA control of blood coagulation - oestrogen-mediated thrombosis

High oestrogen levels can elevate the risk of developing venous thrombosis (clots in the vein); oestrogen is known to change selected blood coagulation processes. PBI’s research team looked at identifying what mechanisms or compounds are potentially involved. This research led to PBI being the first to understand that a small group of molecules called ‘microRNAs’ are vital in controlling blood coagulation. MicroRNAs can control the manufacturing of proteins which is the final functional product in the body.

This discovery resulted in the finding that microRNAs are involved in regulating one anticoagulation protein – Protein S (PS) and one pro-coagulation protein Tissue Factor (TF). PS is involved in halting a progressing blood coagulation cascade, and TF is important in initiating clots when required. High oestrogen levels can lead to reduced PS and a deficiency of PS could lead to unexpected clotting events. Conversely, elevated oestrogen levels can result in increasing the amount of TF in blood circulation, thus promoting blood coagulation.  Any irregularities in the anticoagulation and pro-coagulation processes elevates clotting risk in women with high oestrogen levels.

These findings provide crucial information on understanding the connection between oestrogen and thrombosis. Moreover, microRNAs are a powerful tool to have in developing personalised precision medicines. 

This research has resulted in new miR-based related blood diagnostic tests and miR-based therapies currently being developed.


Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP) is a rare and fatal disease caused by a deficiency of the Von Willebrand factor cleaving enzyme, ADAMTS-13. ADAMTS-13 deficiency can be hereditary, but more often is an acquired disorder due to the production of inhibitory autoantibodies. It occurs in around 20 patients per year per million people. The PBI research division leads the Asia Pacific Microangiopathy Thrombocytopenia (APMAT) Network across 24 leading centres in the Asia Pacific (AP) to rapidly collect and bio-bank clinical material on a large number of patients with Thrombotic Microangiopathy. Our work has standardised diagnostic ADAMTS-13 testing in the AP region, and utilising the APMAT bio-bank we are exploring new diagnostic algorithms and developing new molecular testing.

Our understanding of the rare TTP disease has led to a proposal for further research on the disease and a global standardisation study of ADAMTS13 testing.


Chronic Lymphocytic Leukaemia

Bleeding is a common complication of advanced chronic lymphocytic leukaemia (CLL). PBI’s research discovered important cancer-related platelet dysfunctions, which could contribute to the exacerbated bleeding phenotype seen in CLL patients.  This could be particularly significant in malignant CLL clone and/or therapeutic interventions, where further impaired platelet function could be at play. One study examined Bruton’s tyrosine kinase inhibitors (eg. ibrutinib, acalabrutinib) and their effect on blood samples collected from patients. These drugs are known to inhibit platelet aggregation mediated by glycoprotein VI (GPVI) and other platelet signalling pathways. Furthermore, the study examined the anti-platelet effects of BH3 mimetics (eg. venetoclax), a less well understood property of the drug. CLL is associated with a broad platelet functional defect, which persists despite the clinical benefits of ibrutinib or venetoclax treatment.

Results of the study showed that ibrutinib, not venetoclax, induces additive inhibition of platelet function in CLL patients, that is not related to altered GPVI cleavage. Additionally, it was shown that clinically-utilised whole blood platelet function assays are capable of quantifying the degree of functional impairment in CLL patients - a world first observation made by PBI scientists.

Back to top

Showing 10 of 0

Latest

  • Gemma's story

    Gemma's story

    No one wants to face it; I didn't look like a cancer patient.

  • Myelofibrosis (MF)

    Myelofibrosis (MF)

    Myelofibrosis is an uncommon type of blood cancer that interrupts the body’s normal production of blood cells.

  • Andrew's story

    Andrew's story

    Andrew was diagnosed with myelofibrosis in 2021, an uncommon form of blood cancer affecting the bone marrow. Learn more about Andrew's story here.

  • Rare Disease Day 2023

    Rare Disease Day 2023

    February 28 is Rare Disease Day. This global initiative provides an opportunity to increase awareness about rare disorders which can affect everyone.

Most read

  • What is thrombosis?

    What is thrombosis?

    Click here to learn more about thrombosis.

  • What are DVT & PE?

    What are DVT & PE?

    Click here to learn more about DVT and PE.

  • Antiphospholipid Antibody Syndrome

    Antiphospholipid Antibody Syndrome

    Click here for information about antiphospholipid antibody syndrome and how it can lead to thrombosis.

  • Work and Thrombosis

    Work and Thrombosis

    Click here to learn more about how work can increase your risk of thrombosis, and how to prevent it.

  • Contraception and Thrombosis

    Contraception and Thrombosis

    Click here to learn more about how certain contraceptives can increase your risk of dangerous blood clots.

  • Inherited Thrombophilias

    Inherited Thrombophilias

    Click here for information about genetic conditions that can increase the chances of thrombosis.

  • Investigators

    Investigators

  • Travel and Thrombosis

    Travel and Thrombosis

    Click here to learn about how travel can increase your risk of developing dangerous blood clots.

  • Participate in a clinical trial

    Participate in a clinical trial

    PBI's Clinical Trials Unit actively runs numerous clinical trials and performs state-of-the-art research into bleeding and clotting disorders and blood cancers.

  • Pregnancy and Thrombosis

    Pregnancy and Thrombosis

    Click here to learn about how pregnancy can increase your risk of thrombosis.

Tag cloud

Acute Myeloid Leukaemia ADAMTS13 blood clots cancer contraceptive Follicular Lymphoma haemophilia A Microangiopathic Thrombocytopenia multiple myeloma oral contraceptive pregnancy Relapsed Multiple Myeloma small vessels thrombosis Thrombotic Thrombocytopaenic Pupura TMA
Donate today

Donate today

Please help to make blood disorders a thing of the past. Every amount is vital to our research, no matter how large or small. Read more

Donate Fundraise

Published: 18th February, 2020

Updated: 9th February, 2023

Author:

Elie's story

Elie's story

When Elie was a young, fit and healthy 22-year-old he noticed a lump in the side of his neck. He went to his GP complaining of fatigue, insomnia, and severe itching. After being misdiagnosed with glandular fever and then a mystery virus, he received a call from his doctor. Read more

Published: 9th July, 2020

Updated: 28th March, 2022

Author: Jake Harfield

Purchase a Entertainment™ Digital Membership and support PBI

Purchase a Entertainment™ Digital Membership and support PBI

Gain access to over 20,000 local & national offers and support Perth Blood Institute at the same time. Read more

Published: 2nd August, 2021

Updated: 25th January, 2022

Author: Bec Morgan

Perth Blood Institute benefits from family ties

Perth Blood Institute benefits from family ties

The family of a Perth mum who has a blood condition so rare that she’s almost one in a million is rallying behind her – and gaining support from numerous work colleagues. Read more

Published: 21st February, 2022

Updated: 4th April, 2022

Author: Felicity Barnes

Celebrating World Health Day

Celebrating World Health Day

In recogntion of WHD 2022, find out how our patients look after their physical and mental wellbeing while living with a blood disorder. Read more

Published: 28th March, 2022

Updated: 8th February, 2023

Author: Felicity Barnes

Sign up for our newsletter

Please enter your first name
Please enter your last name
Please enter your email address Please enter a valid email address (e.g. [email protected])

Helpful links

  • Sitemap
  • Accessibility
  • Terms & conditions
  • Privacy policy
  • Contact us

Contact

18 Prowse Street
West Perth
WA 6005
P : +61 8 9200 5300
F : +61 8 9200 5324
E : [email protected]

  • Facebook
  • Instagram
  • Linkedin
  • Email

PBI is registered as an Income Tax Exempt Charity
CFN: CC21886
ACN: 164 941 815
ABN: 24 164 941 815

© Perth Blood Institute 2020